Cargando…

Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore

Introduction: We compared the early total spike antibody (S-Ab) and neutralizing antibody (N-Ab) responses to two vaccines. Methods: We studied 96 Pfizer and 34 Sinovac vaccinees over a 14-month period from January 2021 to February 2022. All vaccinees received three doses of one type of vaccine. Ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Chin Shern, Oh, May Lin Helen, Phua, Soon Kieng, Liang, Ya Li, Li, Yanfeng, Huo, Jianxin, Huang, Yuhan, Zhang, Biyan, Xu, Shengli, Aw, Tar Choon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220327/
https://www.ncbi.nlm.nih.gov/pubmed/35735357
http://dx.doi.org/10.3390/antib11020038
_version_ 1784732346389364736
author Lau, Chin Shern
Oh, May Lin Helen
Phua, Soon Kieng
Liang, Ya Li
Li, Yanfeng
Huo, Jianxin
Huang, Yuhan
Zhang, Biyan
Xu, Shengli
Aw, Tar Choon
author_facet Lau, Chin Shern
Oh, May Lin Helen
Phua, Soon Kieng
Liang, Ya Li
Li, Yanfeng
Huo, Jianxin
Huang, Yuhan
Zhang, Biyan
Xu, Shengli
Aw, Tar Choon
author_sort Lau, Chin Shern
collection PubMed
description Introduction: We compared the early total spike antibody (S-Ab) and neutralizing antibody (N-Ab) responses to two vaccines. Methods: We studied 96 Pfizer and 34 Sinovac vaccinees over a 14-month period from January 2021 to February 2022. All vaccinees received three doses of one type of vaccine. Antibody levels (Roche Elecsys total S-Ab and the Snibe N-Ab) were tested 10 days after the first dose, 20 days after the second dose, and 20 days after the booster dose. Results: At all time points, the mRNA vaccine generated higher S-Ab and N-Ab responses than the inactivated virus vaccine (S-Ab: first dose 2.48 vs. 0.4 BAU/mL, second dose 2174 vs. 98 BAU/mL, third dose 15,004 vs. 525 BAU/mL; N-Ab: first dose 0.05 vs. 0.02 µg/mL, second dose 3.48 vs. 0.38 µg/mL, third dose 19.8 vs. 0.89 µg/mL). mRNA vaccine recipients had a 6.2/22.2/28.6-fold higher S-Ab and 2.5/9.2/22.2-fold higher N-Ab response than inactivated virus vaccine recipients after the first/second/third inoculations, respectively. Mann–Whitney U analysis confirmed the significant difference in S-Ab and N-Ab titers between vaccination groups at each time point. Conclusions: The mRNA vaccines generated a more robust S-Ab and N-Ab response than the inactivated virus vaccine at all time points after the first, second, and third vaccinations.
format Online
Article
Text
id pubmed-9220327
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92203272022-06-24 Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore Lau, Chin Shern Oh, May Lin Helen Phua, Soon Kieng Liang, Ya Li Li, Yanfeng Huo, Jianxin Huang, Yuhan Zhang, Biyan Xu, Shengli Aw, Tar Choon Antibodies (Basel) Article Introduction: We compared the early total spike antibody (S-Ab) and neutralizing antibody (N-Ab) responses to two vaccines. Methods: We studied 96 Pfizer and 34 Sinovac vaccinees over a 14-month period from January 2021 to February 2022. All vaccinees received three doses of one type of vaccine. Antibody levels (Roche Elecsys total S-Ab and the Snibe N-Ab) were tested 10 days after the first dose, 20 days after the second dose, and 20 days after the booster dose. Results: At all time points, the mRNA vaccine generated higher S-Ab and N-Ab responses than the inactivated virus vaccine (S-Ab: first dose 2.48 vs. 0.4 BAU/mL, second dose 2174 vs. 98 BAU/mL, third dose 15,004 vs. 525 BAU/mL; N-Ab: first dose 0.05 vs. 0.02 µg/mL, second dose 3.48 vs. 0.38 µg/mL, third dose 19.8 vs. 0.89 µg/mL). mRNA vaccine recipients had a 6.2/22.2/28.6-fold higher S-Ab and 2.5/9.2/22.2-fold higher N-Ab response than inactivated virus vaccine recipients after the first/second/third inoculations, respectively. Mann–Whitney U analysis confirmed the significant difference in S-Ab and N-Ab titers between vaccination groups at each time point. Conclusions: The mRNA vaccines generated a more robust S-Ab and N-Ab response than the inactivated virus vaccine at all time points after the first, second, and third vaccinations. MDPI 2022-05-27 /pmc/articles/PMC9220327/ /pubmed/35735357 http://dx.doi.org/10.3390/antib11020038 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lau, Chin Shern
Oh, May Lin Helen
Phua, Soon Kieng
Liang, Ya Li
Li, Yanfeng
Huo, Jianxin
Huang, Yuhan
Zhang, Biyan
Xu, Shengli
Aw, Tar Choon
Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore
title Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore
title_full Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore
title_fullStr Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore
title_full_unstemmed Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore
title_short Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore
title_sort kinetics of the neutralizing and spike sars-cov-2 antibodies following the sinovac inactivated virus vaccine compared to the pfizer mrna vaccine in singapore
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220327/
https://www.ncbi.nlm.nih.gov/pubmed/35735357
http://dx.doi.org/10.3390/antib11020038
work_keys_str_mv AT lauchinshern kineticsoftheneutralizingandspikesarscov2antibodiesfollowingthesinovacinactivatedvirusvaccinecomparedtothepfizermrnavaccineinsingapore
AT ohmaylinhelen kineticsoftheneutralizingandspikesarscov2antibodiesfollowingthesinovacinactivatedvirusvaccinecomparedtothepfizermrnavaccineinsingapore
AT phuasoonkieng kineticsoftheneutralizingandspikesarscov2antibodiesfollowingthesinovacinactivatedvirusvaccinecomparedtothepfizermrnavaccineinsingapore
AT liangyali kineticsoftheneutralizingandspikesarscov2antibodiesfollowingthesinovacinactivatedvirusvaccinecomparedtothepfizermrnavaccineinsingapore
AT liyanfeng kineticsoftheneutralizingandspikesarscov2antibodiesfollowingthesinovacinactivatedvirusvaccinecomparedtothepfizermrnavaccineinsingapore
AT huojianxin kineticsoftheneutralizingandspikesarscov2antibodiesfollowingthesinovacinactivatedvirusvaccinecomparedtothepfizermrnavaccineinsingapore
AT huangyuhan kineticsoftheneutralizingandspikesarscov2antibodiesfollowingthesinovacinactivatedvirusvaccinecomparedtothepfizermrnavaccineinsingapore
AT zhangbiyan kineticsoftheneutralizingandspikesarscov2antibodiesfollowingthesinovacinactivatedvirusvaccinecomparedtothepfizermrnavaccineinsingapore
AT xushengli kineticsoftheneutralizingandspikesarscov2antibodiesfollowingthesinovacinactivatedvirusvaccinecomparedtothepfizermrnavaccineinsingapore
AT awtarchoon kineticsoftheneutralizingandspikesarscov2antibodiesfollowingthesinovacinactivatedvirusvaccinecomparedtothepfizermrnavaccineinsingapore